- Home
- ALRS vs RIGL Comparison
ALRS vs RIGL Comparison
Compare ALRS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALRS | RIGL |
|---|---|---|
| Founded | 1879 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 831.8M | 884.9M |
| IPO Year | 2019 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ALRS | RIGL |
|---|---|---|
| Price | $31.71 | $47.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $35.40 | ★ $63.00 |
| AVG Volume (30 Days) | 121.5K | ★ 156.8K |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | ★ 1.70 | 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $5.94 | $3.89 |
| Revenue Next Year | $2.67 | $21.95 |
| P/E Ratio | ★ $18.65 | $37.33 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $20.31 | $24.84 |
| 52 Week High | $34.40 | $52.24 |
Technical Indicators
Market Signals| Indicator | ALRS | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 54.74 |
| Support Level | $30.13 | $43.78 |
| Resistance Level | $31.86 | $49.50 |
| Average True Range (ATR) | 0.67 | 1.61 |
| MACD | -0.15 | -0.09 |
| Stochastic Oscillator | 0.00 | 65.54 |
Price Performance
Historical ComparisonAbout ALRS Alerus Financial Corporation
Alerus Financial Corp is a financial holding company registered in the United States. The company operates in four segments: Banking, Retirement & Benefit Services, Wealth Management, and others. The company provides various banking services such as checking, debit cards, savings, current deposits, loans and advances, online banking, mobile banking, private banking, payment solutions, and other business products. Additionally, the company provides mortgage loans, retirement planning solutions, individual retirement accounts, retirement plan advisory services and wealth management services, including retirement plans, and fiduciary services. The company's revenue mainly consists of interest income, commission, management fees, and other income.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.